Abstract
Glioblastoma (GBM) is the most common and malignant type of glioma. The resistance of these tumors to treatment is a major challenge to be overcome in order to obtain the most successful therapies applied to patients with GBM, whose survival does not exceed 15 months after diagnosis. Thus, it becomes relevant to investigate the mechanisms involved in GBM resistance to anticancer agents. T…